Product Information
KETAMINE 500 MG/10 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $0.5563 per ML under NDC 65219018810. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on Jan 13, 2023. Its Orange Book therapeutic-equivalence code is AP.
Strength
50 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
65219018810
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
KETAMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215808FDA Approved
1/13/2023
TE Code
AP
On Market Since
7/10/2023
Pharmacological Classes
Price Statistics
The NADAC for KETAMINE 500 MG/10 ML VIAL has been published 42 times since Dec 17, 2025, and over the history we have for it it has risen 4.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5563 per ML |
|---|---|
| All-time high | $0.5579 (Sep 16, 2026) |
| All-time low | $0.5213 (Mar 18, 2026) |
| 52-week high | $0.5579 |
| 52-week low | $0.5213 |
| Median price | $0.5331 |
| Average price | $0.5361 |
| Largest weekly change | +3.0% (Jun 17, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ketamine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ketamine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
General Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KETAMINE 500 MG/10 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for KETAMINE 500 MG/10 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $0.5563 per ML (NDC 65219018810), effective Sep 30, 2026.
How has the price of KETAMINE 500 MG/10 ML VIAL changed over time?
Over the history we have for it, the NADAC for KETAMINE 500 MG/10 ML VIAL has risen 4.4%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for KETAMINE 500 MG/10 ML VIAL?
Since Dec 17, 2025, the NADAC for KETAMINE 500 MG/10 ML VIAL has ranged from a low of $0.5213 (Mar 18, 2026) to a high of $0.5579 (Sep 16, 2026), with a median of $0.5331 per ML.
Are there cheaper alternatives to KETAMINE 500 MG/10 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of KETAMINE 500 MG/10 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures KETAMINE 500 MG/10 ML VIAL?
KETAMINE 500 MG/10 ML VIAL (NDC 65219018810) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.